비경변성 문맥 고혈압의 자연사
Background:
- Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure in the blood vessels of the liver. It seems to start slowly and not have many warning signs. Many people may not even know that they have a liver disease. There are no specific treatments for NCPH.
Objectives:
- To learn more about how NCPH develops over time.
Eligibility:
- People age 12 and older who have NCPH or are at risk for getting it. In the past year, they cannot have had other types of liver disease that typically result in cirrhosis, liver cancer, or active substance abuse.
Design:
- Participants will have 2 screening visits.
- Visit 1: to see if they have or may develop NCPH.
- Medical history
- Physical exam
- Urine and stool studies
- Abdominal ultrasound
- Fibroscan. Sound waves measure liver stiffness.
<TAB>- Visit 2:
- Blood tests
- Abdominal MRI
- Echocardiogram
- Questionnaire
- Liver blood vessel pressure (hepatic venous portal gradient (HVPG)) measurement. This is done with a small tube inserted in a neck vein.
- They may have a liver biopsy.
- All participants will visit the clinic every 6 months for a history, physical exam, and blood tests. They will also repeat some of the screening tests yearly.
- Participants with NCPH will also have:
- Upper endoscopy test. A tube inserted in the mouth goes through the esophagus and stomach.
- At least every 2 years: Esophagogastroduodenoscopy.
- At least every 4 years: testing including HVPG measurements and liver biopsy.
- Participants without NCPH will also have:
- Liver biopsy and HVPG measurements to see if they have NCPH.
- Every 2 years: abdominal MRI and stool studies.
- The study will last indefinitely.
연구 개요
상태
상태
정황
정황
상세 설명
Study Description:
Up to 400 subjects with noncirrhotic portal hypertension or at risk for developing noncirrhotic portal hypertension by virtue of their
underlying disease (as well as sporadic cases of noncirrhotic portal hypertension as referred to in this protocol) will be offered inclusion
in the study.
Objectives:
Primary Objective:
1. The goal of this natural history study is to generate understanding of the development and progression of NCPH. We will use our
findings to generate novel biomarkers that will enable improved follow-up of patients, assist in preventing complications, and
enhance transplant decision.
Secondary Objectives:
- Measurement of the bile acids and lipids to understand NCPH and porto-systemic shunting.
- Identification of the genetic modifiers of NCPH.
- Evaluation of hepatic transcriptome in absence and presence of NCPH.
- Characterization of microbiome signatures in NCPH.
Endpoints:
Primary Endpoints:
- Establish surveillance methods and guidelines for evaluation of NCPH.
- Develop an understanding of the biological mechanisms of the progression of NCPH.
- Identification of novel biomarkers correlating with NCPH progression.
Secondary Endpoints:
- Measurement of bile acids fractionated and total, as well as lipid panel to establish cut-off levels correlating with NCPH severity.
- Establishment of positive or negative correlation between candidate susceptible genes and disease phenotype.
- Identification of novel markers of fibrosis or the development of hepatic neoplasia from transcriptome analysis.
- Characterization of microbiome signatures (taxonomic and functional), as well as identification of specific species.
연구 유형
연구 유형
등록 (추정된)
등록
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Theo Heller, M.D.
- 전화번호: (301) 402-7147
- 이메일: theoh@intra.niddk.nih.gov
연구 연락처 백업
- 이름: Jaha F Norman-Wheeler
- 전화번호: (301) 435-6122
- 이메일: jaha.norman-wheeler@nih.gov
연구 장소
-
-
Maryland
-
Bethesda, Maryland, 미국, 20892
- 모병
- National Institutes of Health Clinical Center
-
연락하다:
- Jaha Norman-Wheeler
- 전화번호: 301-435-6122
- 이메일: jaha.norman-wheeler@nih.gov
-
연락하다:
- For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
- 전화번호: TTY dial 711 (800) 411-1222
- 이메일: ccopr@nih.gov
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Subjects with diagnosis of noncirrhotic portal hypertension above age of 12 years
설명
- INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Male or female, aged >= 18 years of age, and minors 12-17 years of age.
- Women of childbearing potential must agree to use birth control unless they are menopausal or had hysterectomy.
- Known diagnosis of NCPH, or to be at the risk for NCPH by virtue of underlying disease processes such as but not limited to; CGD, SCD, Mastocytosis, CVID, CF, and CHF.
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study:
- Pregnancy.
- Evidence of other forms of liver disease that typically result in cirrhosis.
- Evidence of active Chronic Hepatitis B infection as defined by the presence of hepatitis B surface antigen (HBsAg) in serum and elevated HBV DNA (>10,000 IU/mL).
- Hepatitis C as defined by the presence of hepatitis C RNA in serum.
- Evidence of other liver disease such as primary sclerosing cholangitis, primary biliary cirrhosis, Wilson s disease, autoimmune hepatitis as defined by either liver histology or laboratory abnormalities.
- Hemochromatosis as defined by presence of 3+ or 4+ stainable iron on liver biopsy or homozygosity for C282Y. Patients with iron saturation indices of >45% and serum ferritin levels of >300 ng/ml for men and >250 ng/ml for women will undergo genetic testing for hemochromatosis.
- Bile duct obstruction as suggested by imaging studies done within the previous six months.
- The presence of cirrhosis confirmed by liver biopsy.
- Active substance abuse, such as alcohol, inhaled or injection drugs within the previous one year (assessed during subject interviews by subject self-report).
- Evidence of hepatocellular carcinoma; either alpha-fetoprotein (AFP) levels greater than 50 ng/ml (normal <6.6ng/ml) and/or ultrasound (or other imaging study) demonstrating a mass suggestive of liver cancer.
- Evidence of cholangiocarcinoma as suggested by liver histology.
- Any other severe condition, which in the opinion of the investigators would impede the patient s participation or compliance in the study.
- Inability to comply or give written informed consent.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
|---|
|
Adult with absence of Portal Hypertension
Confirmed absence of Portal Hypertension will have no findings suggestive of non cirrhotic portal hypertension on liver biopsy and on portal pressure measurements on confirmatory examination. |
|
Adult with presence of Portal Hypertension
Confirmed Presence of Noncirrhotic Portal Hypertension, through confirmatory testing, tissue diagnosis by liver biopsy and/or portal hypertension (HVPG >5mmHg). |
|
Minors likely to have the absence of Portal Hypertension
Minors identified as Confirmed Absence of Noncirrhotic Portal Hypertension will have no abnormal findings on confirmatory examination. |
|
Minors likely to have the presence of Portal Hypertension
Minors identified as Confirmed Presence of Noncirrhotic Portal Hypertension, have shown they have the disease with a tissue diagnosis by liver biopsy and/or portal hypertension (HVPG >5). |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
To study the natural history of non cirrhotic portal hypertension. It is an ongoing study.
기간: Ongoing
|
natural history study |
Ongoing
|
공동 작업자 및 조사자
스폰서
스폰서
수사관
수사관
- 수석 연구원: Theo Heller, M.D., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
간행물 및 유용한 링크
일반 간행물
- Sarin SK, Aggarwal SR. Idiopathic portal hypertension. Digestion. 1998 Jul-Aug;59(4):420-3. doi: 10.1159/000007502. No abstract available.
- Sarin SK, Kumar A, Chawla YK, Baijal SS, Dhiman RK, Jafri W, Lesmana LA, Guha Mazumder D, Omata M, Qureshi H, Raza RM, Sahni P, Sakhuja P, Salih M, Santra A, Sharma BC, Sharma P, Shiha G, Sollano J; Members of the APASL Working Party on Portal Hypertension. Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment. Hepatol Int. 2007 Sep;1(3):398-413. doi: 10.1007/s12072-007-9010-9. Epub 2007 Sep 11.
- Schouten JN, Garcia-Pagan JC, Valla DC, Janssen HL. Idiopathic noncirrhotic portal hypertension. Hepatology. 2011 Sep 2;54(3):1071-81. doi: 10.1002/hep.24422. Epub 2011 Jul 21.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정된)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 비뇨생식기 질환
- 내분비계 질환
- 혈관 질환
- 심혈관 질환
- 남성 비뇨 생식기 질환
- 병리학적 상태, 해부학적
- 여성 비뇨 생식기 질환
- 여성 비뇨 생식기 질환 및 임신 합병증
- 심장 질환
- 유전병, 선천적
- 면역계 질환
- 호흡기 질환
- 소화기계 질환
- 폐 질환
- 유아, 신생아, 질병
- 췌장 질환
- 생식선 장애
- 선천적 이상
- 심혈관 이상
- 심장 결함, 선천성
- 성 발달 장애
- 비뇨 생식기 이상
- 성 염색체 장애
- 염색체 장애
- 성발달의 성염색체 장애
- 비대
- 생식선 이형성증
- 선천성, 유전성, 신생아 질환 및 이상
- 병리학적 상태, 징후 및 증상
- 특발성 비경변성 문맥 고혈압
- 간 질환
- 면역 결핍 증후군
- 고혈압, 포털
- 낭포성 섬유증
- 정맥류
- 터너 증후군
- 비장 비대
- 간 섬유증, 선천성
기타 연구 ID 번호
기타 연구 ID 번호
- 150108
- 15-DK-0108
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
This is a longitudinal study and it is not yet known if and when IPD will be made available.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .